Cover Image
市場調查報告書

已開發國家的腸胃治療藥市場:為了對抗專利失效的收益減少,新藥的認證與有前途的開發中產品

Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries

出版商 GBI Research 商品編碼 294433
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
已開發國家的腸胃治療藥市場:為了對抗專利失效的收益減少,新藥的認證與有前途的開發中產品 Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries
出版日期: 2014年01月27日 內容資訊: 英文
簡介

已開發國家的腸胃治療藥的市場規模,2012年上升到總額68億美元。還有2012∼2019年的年複合成長率(CAGR)預計為負0.3%。在主要各疾病中,2012年時的市場規模,為大腸躁鬱症(IBS)7億2700萬美元,潰瘍性大腸炎(UC)22億美元,克隆氏症(CD)38億美元。佔Humira和Remicade的銷售額的大半的醫藥品的專利不久將失效,是市場負成長的主要原因。但,透過臨床實驗最後階段有潛力開發中產品的上市,預計將某種程度緩和這個趨勢。

本報告提供主要已開發國家(美國、英國、法國、德國、義大利、西班牙、日本、加拿大)的腸胃相關的治療藥的市場相關分析、疾病概要與特性,及主要已上市產品概要、有前途的開發中產品的資訊、臨床實驗的進展和今後的產品上市預測、各國市場趨勢預測(今後6年份)、資本交易與業務聯盟的主要動向等調查,並將結果概述為以下內容。

第1章 目錄

第2章 已開發國家的腸胃治療藥市場:簡介

  • 大腸躁鬱症
  • 潰瘍性大腸炎
  • 克隆氏症

第3章 已上市產品(全球)

  • 大腸躁鬱症
  • 潰瘍性大腸炎
  • 克隆氏症
  • 主要的已上市產品
    • Amitiza
    • Humira
    • Remicade
    • Simponi
    • Cimzia
    • Tysabri

第4章 開發平台分析

  • 大腸躁鬱症
    • 開發平台概況
    • 各分子的種類分析
    • 各行動機制分析
  • 潰瘍性大腸炎的平台
  • 克隆氏症的平台
  • 開發平台上有前途開發平台候補
    • GSK-1605786
    • MLN0002
    • EMD-61753

第5章 市場預測(今後6年份)

  • 先進國家市場
    • 治療方法的利用模式
    • 年度治療費用
    • 市場規模
  • 美國
  • 歐洲
  • 加拿大
  • 日本
  • 推動及阻礙市場要素

第6章 資本交易和策略性企業整合(全球)

  • 資本交易分析
  • 主要共同開發交易(共3件)
  • 主要許可證交易(共3件)

第7章 附錄

圖表一覽

目錄
Product Code: GBIHC318MR

GBI Research, the leading business intelligence provider, has released its latest research, ‘Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries', which provides insights into three gastrointestinal therapeutic indications in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of three gastrointestinal therapeutics markets, namely Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn's Disease (CD). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these three gastrointestinal indications.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research's team of industry experts.

In 2012, the value of the gastrointestinal therapeutics market in major developed countries amounted to an estimated $6.8 billion. This total is forecast to decline at a Compound Annual Growth Rate (CAGR) of 0.3% between 2012 and 2019. The value of the IBS market amounted to an estimated $727m, and is forecast to increase at a CAGR of 14.4% between 2012 and 2019. The value of the UC market amounted to an estimated $2.2 billion in 2012, and is expected to increase at a CAGR of 6% during the forecast period. The value of the CD market amounted to an estimated $3.8 billion, which is expected to decline at a CAGR of 7.5% between 2012 and 2019.

Scope

  • The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals for the IBS, UC and CD indications in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada.
  • Disease overview and treatment usage patterns
  • Market size and forecast for IBS, UC and CD in major developed markets from 2012 to 2019
  • Major marketed products for the indication types covered
  • In-depth pipeline analysis for IBS, UC and CD
  • Key drivers and restraints that have had and are expected to have a major impact upon the market
  • Key licensing and co-development agreements in the gastrointestinal therapeutics market

Reasons to buy

  • Align your product portfolio to the markets with high growth potential
  • Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments that are poised for strong growth
  • Devise a more effectively tailored country-specific strategy through the understanding of key drivers and barriers in the gastrointestinal therapeutics market
  • Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships

Abstract

Gastrointestinal Therapeutics Industry: Promising Drugs in Late-Stage Development Could Stabilize Declining Global Market, says GBI Research.

The gastrointestinal (GI) therapeutics market for irritable bowel syndrome (IBS), ulcerative colitis (UC), and Crohn's disease (CD) in the eight major markets (8MM) - the US, UK, France, Germany, Italy, Spain, Canada and Japan - is expected to decrease in value from $6.8 billion in 2012 to $6.6 billion by 2019, at a negative Compound Annual Growth Rate (CAGR) of 0.3%, forecasts business intelligence provider GBI Research.

According to the firm's latest report*, the GI market will register different CAGRs across the 8MM during the forecast period. The US and Japan will witness positive CAGRs of 0.2% and 4%, respectively, while the European markets will decline at a negative CAGR of 2.5%. This unfavourable growth is due to the upcoming patent expiry of various major drugs.

Arti Singh, Analyst for GBI Research, says: "As Humira and Remicade account for a substantial share of the GI therapeutics industry, their patent expiries will harm the overall market value. The entry of generics and biosimilars will also have a strong impact on sales."

However, promising pipeline drugs in the late stages of development could stabilize the current market.

Singh continues: "Three molecules in the pre-registration stage of development are expected to be approved during the forecast period. Of these molecules, one - vedolizumab - is indicated for the treatment of both UC and CD. The second molecule is a biosimilar of blockbuster drug Remicade (infliximab) and is expected to be launched following Remicade's patent expiry."

Additionally, almost 51% of the overall GI pipeline is in Phase II and Phase III development, of which 19 molecules are indicated for the treatment of IBS, 48 for UC and 41 for CD.

"The major factors currently stabilizing the market include the increasing prevalence of GI diseases, growing awareness of the importance of detecting these diseases early and the availability of effective diagnostics," the analyst concludes.

Gastrointestinal Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Counter Declines from Patent Expiries

This report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals for the irritable bowel syndrome, ulcerative colitis and Crohn's disease indications in the eight major markets - the US, UK, France, Germany, Italy, Spain, Canada and Japan.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research's team of industry experts.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Gastrointestinal Therapeutics in Major Developed Markets - Introduction

  • 2.1. Irritable Bowel Syndrome
    • 2.1.1. Classification
    • 2.1.2. Symptoms
    • 2.1.3. Etiology
    • 2.1.4. Pathophysiology
    • 2.1.5. Diagnosis
    • 2.1.6. Epidemiology
    • 2.1.7. Prognosis
    • 2.1.8. Treatment Options
  • 2.2. Ulcerative Colitis
    • 2.2.1. Classification
    • 2.2.2. Symptoms
    • 2.2.3. Etiology
    • 2.2.4. Pathophysiology
    • 2.2.5. Diagnosis
    • 2.2.6. Epidemiology
    • 2.2.7. Prognosis
    • 2.2.8. Treatment Options
  • 2.3. Crohn's Disease
    • 2.3.1. Classification
    • 2.3.2. Symptoms
    • 2.3.3. Etiology
    • 2.3.4. Pathophysiology
    • 2.3.5. Diagnosis
    • 2.3.6. Epidemiology
    • 2.3.7. Prognosis
    • 2.3.8. Treatment Options

3. Gastrointestinal Therapeutics in Major Developed Markets - Marketed Products (Global)

  • 3.1. Irritable Bowel Syndrome
  • 3.2. Ulcerative Colitis
  • 3.3. Crohn's Disease
  • 3.4. Key Marketed Products
    • 3.4.1. Amitiza
    • 3.4.2. Humira
    • 3.4.3. Remicade
    • 3.4.4. Simponi
    • 3.4.5. Cimzia
    • 3.4.6. Tysabri

4. Gastrointestinal Therapeutics in Major Developed Markets - Pipeline Analysis

  • 4.1. Irritable Bowel Syndrome
    • 4.1.1. Overall Pipeline
    • 4.1.2. Pipeline Analysis by Molecule Type
    • 4.1.3. Pipeline Analysis by Mechanism of Action
  • 4.2. Ulcerative Colitis Pipeline
    • 4.2.1. Overall Pipeline
    • 4.2.2. Pipeline Analysis by Molecule Type
    • 4.2.3. Pipeline Analysis by Mechanism of Action
  • 4.3. Crohn's Disease Pipeline
    • 4.3.1. Overall Pipeline
    • 4.3.2. Pipeline Analysis by Molecule Type
    • 4.3.3. Pipeline Analysis by Mechanism of Action
  • 4.4. Promising Drug Candidates in the Pipeline
    • 4.4.1. GSK-1605786
    • 4.4.2. MLN0002
    • 4.4.3. EMD-61753

5. Gastrointestinal Therapeutics in Major Developed Markets - Market Forecast to 2019

  • 5.1. Major Developed Markets
    • 5.1.1. Treatment Usage Patterns
    • 5.1.2. Annual Cost of Therapy
    • 5.1.3. Market Size
  • 5.2. US
    • 5.2.1. Treatment Usage Patterns
    • 5.2.2. Annual Cost of Therapy
    • 5.2.3. Market Size
  • 5.3. Europe
    • 5.3.1. Treatment Usage Patterns
    • 5.3.2. Annual Cost of Therapy
    • 5.3.3. Market Size
  • 5.4. Canada
    • 5.4.1. Treatment Usage Patterns
    • 5.4.2. Annual Cost of Therapy
    • 5.4.3. Market Size
  • 5.5. Japan
    • 5.5.1. Treatment Usage Patterns
    • 5.5.2. Annual Cost of Therapy
    • 5.5.3. Market Size
  • 5.6. Drivers and Barriers
    • 5.6.1. Drivers
    • 5.6.2. Barriers

6. Gastrointestinal Therapeutics in Major Developed Markets - Deals and Strategic Consolidations (Global)

  • 6.1. Deals Analysis
  • 6.2. Major Co-Development Deals
    • 6.2.1. AstraZeneca Enters into Co-Development Agreement with Ironwood Pharma for Linaclotide
    • 6.2.2. Amgen Enters into Co-development Agreement with AstraZeneca for Five Monoclonal Antibodies
    • 6.2.3. Galapagos and AbbVie Extend GLPG0634KKKKK Development Agreement to Include Crohn's Disease
  • 6.3. Major Licensing Deals
    • 6.3.1. AstraZeneca Enters into Licensing Agreement with Ardelyx for NHE3KKKKK Inhibitor Program
    • 6.3.2. Sanofi-Aventis Enters into Licensing Agreement with Kyowa Hakko Kirin
    • 6.3.3. GlaxoSmithKline Enters into Licensing Agreement with ChemoCentryx

7. Gastrointestinal Therapeutics in Major Developed Markets - Appendix

  • 7.1. All Pipeline Drugs by Phase
    • 7.1.1. Discovery
    • 7.1.2. Preclinical
    • 7.1.3. IND/CTA-filed
    • 7.1.4. Phase I
    • 7.1.5. Phase II
    • 7.1.6. Phase III
    • 7.1.7. Pre-Registration
    • 7.1.8. Undisclosed
  • 7.2. Market Forecasts to 2019
    • 7.2.1. Major Developed Markets
    • 7.2.2. US
    • 7.2.3. Canada
    • 7.2.4. UK
    • 7.2.5. France
    • 7.2.6. Germany
    • 7.2.7. Italy
    • 7.2.8. Spain
    • 7.2.9. Japan
  • 7.3. Market Definitions
  • 7.4. Abbreviations
  • 7.5. Sources
  • 7.6. Research Methodology
    • 7.6.1. Coverage
    • 7.6.2. Secondary Research
    • 7.6.3. Primary Research
    • 7.6.4. Therapeutic Landscape
    • 7.6.5. Geographical Landscape
    • 7.6.6. Pipeline Analysis
  • 7.7. Expert Panel Validation
  • 7.8. Contact Us
  • 7.9. Disclaimer

List of Tables

  • Table 1: Gastrointestinal Therapeutics Market, Irritable Bowel Syndrome, Classification, 2009
  • Table 2: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Recommendations for Irritable Bowel Syndrome, 2009
  • Table 3: Gastrointestinal Therapeutics Market, Major Developed Markets, Classification of Ulcerative Colitis, 2004
  • Table 4: Gastrointestinal Therapeutics Market, Major Developed Markets, Diagnosis of Ulcerative Colitis, 2007
  • Table 5: Gastrointestinal Therapeutics Market, Major Developed Markets, Difference Between Ulcerative Colitis and Crohn's Disease, 2007
  • Table 6: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Options of Ulcerative Colitis, 2011
  • Table 7: Gastrointestinal Therapeutics Market, Major Developed Markets, Classification of Crohn's Disease, 2013
  • Table 8: Gastrointestinal Therapeutics Market, Major Developed Markets, Symptoms of Crohn's Disease, 2012
  • Table 9: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Options for Crohn's Disease , 2009
  • Table 10: Gastrointestinal Therapeutics Market, Global, Pipeline (Discovery), 2013
  • Table 11: Gastrointestinal Therapeutics Market, Global, Pipeline (Preclinical), 2013
  • Table 12: Gastrointestinal Therapeutics Market, Global, Pipeline (IND/CTA-filed), 2013
  • Table 13: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase I), 2013
  • Table 14: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase II), 2013
  • Table 15: Gastrointestinal Therapeutics Market, Global, Pipeline (Phase III), 2013
  • Table 16: Gastrointestinal Therapeutics Market, Global, Pipeline (Pre-Registration), 2013
  • Table 17: Gastrointestinal Therapeutics Market, Global, Pipeline (Undisclosed), 2012
  • Table 18: Gastrointestinal Therapeutics Major Developed Markets, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 19: Gastrointestinal Therapeutics Market, Major Developed Markets, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 20: Gastrointestinal Therapeutics Market, Major Developed Markets, Crohn's Disease, Market Forecast, 2012-2019
  • Table 21: Gastrointestinal Therapeutics Market, US, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 22: Gastrointestinal Therapeutics Market, US, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 23: Gastrointestinal Therapeutics Market, US, Crohn's Disease, Market Forecast, 2012-2019
  • Table 24: Gastrointestinal Therapeutics Market, Canada, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 25: Gastrointestinal Therapeutics Market, Canada, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 26: Gastrointestinal Therapeutics Market, Canada, Crohn's Disease, Market Forecast, 2012-2019
  • Table 27: Gastrointestinal Therapeutics Market, UK, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 28: Gastrointestinal Therapeutics Market, UK, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 29: Gastrointestinal Therapeutics Market, UK, Crohn's Disease, Market Forecast, 2012-2019
  • Table 30: Gastrointestinal Therapeutics Market, France, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 31: Gastrointestinal Therapeutics Market, France, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 32: Gastrointestinal Therapeutics Market, France, Crohn's Disease, Market Forecast, 2012-2019
  • Table 33: Gastrointestinal Therapeutics Market, Germany, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 34: Gastrointestinal Therapeutics Market, Germany, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 35: Gastrointestinal Therapeutics Market, Germany, Crohn's Disease, Market Forecast, 2012-2019
  • Table 36: Gastrointestinal Therapeutics Market, Italy, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 37: Gastrointestinal Therapeutics Market, Italy, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 38: Gastrointestinal Therapeutics Market, Italy, Crohn's Disease, Market Forecast, 2012-2019
  • Table 39: Gastrointestinal Therapeutics Market, Spain, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 40: Gastrointestinal Therapeutics Market, Spain, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 41: Gastrointestinal Therapeutics Market, Spain, Crohn's Disease, Market Forecast, 2012-2019
  • Table 42: Gastrointestinal Therapeutics Market, Japan, Irritable Bowel Syndrome, Market Forecast, 2012-2019
  • Table 43: Gastrointestinal Therapeutics Market, Japan, Ulcerative Colitis, Market Forecast, 2012-2019
  • Table 44: Gastrointestinal Therapeutics Market, Japan, Crohn's Disease, Market Forecast, 2012-2019

List of Figures

  • Figure 1: Gastrointestinal Therapeutics Market, Major Developed Markets, Treatment Algorithm of Ulcerative Colitis, 2007
  • Figure 2: Gastrointestinal Therapeutics Market, Global, Sales of Amitiza ($m), 2006-2012
  • Figure 3: Gastrointestinal Therapeutics Market, Global, Sales of Humira ($bn), 2006-2012
  • Figure 4: Gastrointestinal Therapeutics Market, Global, Sales of Remicade ($bn), 2006-2012
  • Figure 5: Gastrointestinal Therapeutics Market, Global, Sales of Simponi ($m), 2009-2012
  • Figure 6: Gastrointestinal Therapeutics Market, Global, Sales of Cimzia ($m), 2008-2012
  • Figure 7: Gastrointestinal Therapeutics Market, Global, Sales of Tysabri ($m), 2006-2012
  • Figure 8: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline, 2013
  • Figure 9: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline by Molecule Type, 2013
  • Figure 10: Gastrointestinal Therapeutics Market, Global, Irritable Bowel Syndrome, Pipeline by Mechanism of Action, 2012
  • Figure 11: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline, 2013
  • Figure 12: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline by Molecule Type, 2013
  • Figure 13: Gastrointestinal Therapeutics Market, Global, Ulcerative Colitis, Pipeline by Mechanism of Action, 2013
  • Figure 14: Gastrointestinal Therapeutics Market, Global, Crohn's Disease, Pipeline, 2013
  • Figure 15: Gastrointestinal Therapeutics Market, Global, Crohn's Disease, Pipeline by Molecule Type, 2013
  • Figure 16: Gastrointestinal Therapeutics Market, Global, Crohn's Disease, Pipeline by Mechanism of Action, 2013
  • Figure 17: Gastrointestinal Therapeutics Market, Major Developed Markets, Market Size ($bn), 2012-2019
  • Figure 18: Gastrointestinal Therapeutics Market, US, Market Size ($bn), 2012-2019
  • Figure 19: Gastrointestinal Therapeutics Market, Top Five European Countries, Market Size ($bn), 2012-2019
  • Figure 20: Gastrointestinal Therapeutics Market, Canada, Market Size ($m), 2012-2019
  • Figure 21: Gastrointestinal Therapeutics Market, Japan, Market Size ($m), 2012-2019
  • Figure 22: Gastrointestinal Therapeutics Market, Global, Deals, 2006-2013
  • Figure 23: Gastrointestinal Therapeutics Market, Global, Co-Development Deals, 2006-2013
  • Figure 24: Gastrointestinal Therapeutics Market, Global, Licensing Deals, 2006-2013
  • Figure 25: GBI Research Market Forecasting Model
Back to Top